Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Decreases By 91.3%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant decrease in short interest in the month of May. As of May 15th, there was short interest totaling 387 shares, a decrease of 91.3% from the April 30th total of 4,431 shares. Based on an average daily trading volume, of 30,829 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC bought a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma as of its most recent SEC filing. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Price Performance

Shares of MTNB traded up $0.09 during trading hours on Thursday, hitting $0.82. 45,319 shares of the stock were exchanged, compared to its average volume of 96,441. Matinas Biopharma has a fifty-two week low of $0.48 and a fifty-two week high of $3.09. The business has a 50-day moving average of $0.59 and a 200-day moving average of $0.67. The firm has a market capitalization of $5.26 million, a P/E ratio of -0.41 and a beta of 1.61.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its earnings results on Friday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.